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ABSTRACT
Background: Patients with adenomatous colonic
polyps are at increased risk of developing further
polyps suggesting field-wide alterations in cancer
predisposition. The current study aimed to identify
molecular alterations in the normal mucosa in the
proximity of adenomatous polyps and to assess the
modulating effect of butyrate, a chemopreventive
compound produced by fermentation of dietary
residues.
Methods: A cross-sectional study was undertaken in
patients with adenomatous polyps: biopsy samples
were taken from the adenoma, and from
macroscopically normal mucosa on the contralateral
wall to the adenoma and from the mid-sigmoid colon.
In normal subjects biopsies were taken from the mid-
sigmoid colon. Biopsies were frozen for proteomic
analysis or formalin-fixed for immunohistochemistry.
Proteomic analysis was undertaken using iTRAQ
workflows followed by bioinformatics analyses.
A second dietary fibre intervention study arm used the
same endpoints and sampling strategy at the beginning
and end of a high-fibre intervention.
Results: Key findings were that keratins 8, 18 and
19 were reduced in expression level with progressive
proximity to the lesion. Lesional tissue exhibited
multiple K8 immunoreactive bands and overall reduced
levels of keratin. Biopsies from normal subjects with
low faecal butyrate also showed depressed keratin
expression. Resection of the lesion and elevation of
dietary fibre intake both appeared to restore keratin
expression level.
Conclusion: Changes in keratin expression associate
with progression towards neoplasia, but remain
modifiable risk factors. Dietary strategies may improve
secondary chemoprevention.
Trial registration number: ISRCTN90852168.
INTRODUCTION
Metachronous adenoma (AD) is a greater
risk than incident AD,1 an observation that
has been used in support of a theory of
colonic field effects. The existence of field
effects around lesions or giving rise to
lesions was proposed over 50 years ago.2 In
the case of the colon, there is debate on
whether the immediate region around the
lesion or the entire colon represents the
field. We have recently summarised the evi-
dence and proposed a series of qualitative
Summary box
What is already known about this subject?
▸ Factors affecting adenomagenesis and carcino-
genesis are thought to be different. Previous
work has shown that the relative risks of each
vary between populations. Patients with a
history of adenoma are at greater risk of meta-
chronous adenoma, which may support the
existence of colorectal fields. To date, little is
known about the molecular basis for such
fields.
▸ Keratins are a type of intermediate filament pro-
teins, which as part of cellular cytoskeleton have
important regulatory functions on the colonic
mucosa. K8 null mice develop colitis and K8 is
shown to modulate tumour necrosis factor
(TNF) action.
▸ Butyrate is widely hypothesised as being a key
chemoprotective molecule, through effects on
cellular programming and cell fate determination
and more recently through regulation of meta-
bolic phenotype of the cell.
What are the new findings?
▸ Validated proteomic analysis of the macroscop-
ically normal mucosa in the colon of participants
with an adenoma was compared to tissue from
the adenoma and from participants free of path-
ology. The analysis indicated that several groups
of proteins were altered, but particularly proteins
of the keratin family.
▸ These data suggest that there may be field-wide
changes in the colon associating with the pres-
ence of a lesion, and contribute to the molecular
evidence for existence of fields.
▸ These changes may be restored to a normal
phenotype (for keratins) by resection of lesions
and by dietary fibre interventions.
Evans CA, Rosser R, Waby JS , et al. BMJ Open Gastro 2015;2:e000022. doi:10.1136/bmjgast-2014-000022 1
Colorectal neoplasia
models for metachronous AD.3 Direct molecular evi-
dence of field effects in the colon has remained elusive
but a gel-based proteomic analysis by Polley et al4 identi-
fied proteins altered in the vicinity of ADs, including
keratin 8. This study supported fields being local to the
lesion, but did not examine sites distant to the lesion.
Additional indirect evidence for crypt expansion to
fields comes from measuring extent of hyperploidy and
crypt expansion in patients with colitis.5 Nonetheless,
direct evidence for molecular changes in colorectal
fields remains limited.
Keratins are key components of intermediate fila-
ments, a cytoskeletal structure responsible for the struc-
tural integrity of the epithelium through cell-cell
contacts, cell shear stress and through regulation of
signal transduction and cell polarisation. Keratin expres-
sion occurs in specific combinations, dependent on the
type of epithelium, and differentiation status related to
the epithelial type and stage of cellular differentiation.6
K8, K18 and K19 are the predominantly expressed in
colonic epithelium.7 Keratin 8 (K8) forms a heterodimer
with keratin 18 (K18) in the colonocyte. Several lines of
evidence suggest a role for K8 in maintenance of a func-
tional colorectal epithelium. Alteration in K8 patterns
occur around colorectal neoplasia4; polymerisation-
inhibiting mutations in K8 were observed in a subset of
inflammatory bowel disease (IBD) patients8; transgenic
mice lacking K8 exhibit hyperplasia in the colon and
impaired barrier and absorptive function in addition to
developing colorectal neoplasia.9 The literature on asso-
ciations between keratin expression, function and colo-
rectal disease has recently been reviewed.7
Keratins (and other proteins in cancer pathways) are
subject to modification by acetylation.10 In the case of
keratin we have shown that acetylation may drive transi-
tion between different protein states (soluble/insol-
uble).11 12 There is substantial evidence from
epidemiological studies to suggest that high dietary fibre
intakes may protect against colorectal cancer.13 14
Mechanisms may include reduction in transit time,
increase in stool volume, both of which would reduce
exposure to carcinogens, and butyrate production.
Butyrate, produced by bacteria-mediated fermentation
regulates cell cycle and apoptosis in vitro,15–17 and is
chemopreventive in rat models of colorectal carcinogen-
esis.18 These properties are attributed to butyrate’s
molecular action as an inhibitor of histone deacetylation
which results in increased protein acetylation.19 Several
microarray-based studies20 21 reveal a substantial portion
of the transcriptome is altered in response to butyrate
but that protein acetylation is not limited to histones
and acetylation is as important in the regulation of
protein function as phosphorylation.22
Proteomic approaches to the analysis of clinical speci-
mens allow objective and impartial evaluation of the
changes occurring between compared samples.
Proteomics is a suite of protein separation and character-
isation approaches, employing gel and gel-free
approaches for protein separation. Two dimensional gel
electrophoresis (2DGE) separates proteins by charge and
mass, gel-free approaches such as isobaric tags for relative
and absolute quantification (iTRAQ) enable quantitative
and global profiling in a multiplex format,23 24 with iden-
tification of larger numbers of proteins, and the relative
quantification of all identifiable proteins, but with the
limitation of loss of separation of subspecies of a protein,
for example distinction of a phosphorylated and non-
phosphorylated species. iTRAQ is an emerging standard
for assessment of changes in a global proteome, while
2DGE has utility for assessment of post-translational mod-
ifications of smaller numbers of species.10
We applied multiple proteomic workflows to protein
extracts from biopsies taken at, near and distant to colo-
rectal neoplasia, stratified by levels of butyrate present
in a stool sample to explore the effects of both colorec-
tal fields and of butyrate on the status of epithelial
keratins.
METHODS AND MATERIALS
Participants and recruitment
This study includes two arms: a cross-sectional study and
a fibre-intervention. The study design has been reported
elsewhere.25 Ethics committee approval was obtained
from the North Sheffield Research Ethics Committee
prior to recruiting (Reference number: 06/Q2308/93).
Cross-sectional study (FACT OBS)
Participants included in this study were recruited from
colonoscopy lists at Sheffield Teaching Hospitals
between October 2007 and June 2008. In total 62 parti-
cipants were included in this analysis, of whom 34 were
found to be free from disease during endoscopy (the
normal group), while 28 participants were found to have
histologically confirmed ADs (the AD group). The
normal group had a younger mean age (62.1±11.4 vs
68.1±0.1, p=0.047). There were no significant differences
between groups for BMI or weight. In patients with
adenomatous polyps biopsies were taken from the AD
itself, and from macroscopically normal mucosa on the
contralateral (CL) wall to the adenoma CL and from
Summary box
How might it impact on clinical practice in the foresee-
able future?
▸ The data provide evidence for the existence of colorectal
fields. As such this introduces the possibility of using
markers (eg, the levels, distributions and form of keratin) as
biomarkers of fields. Critically this work suggests that active
interventions may modulate fields, implying they are regressi-
ble. Both resection and increased intake of fibre rich food
both restored normality to keratin expression. As such sec-
ondary chemopreventive strategies have been proven in prin-
ciple and offer the opportunity to give lifestyle advice to
modulate risk of metachronous disease.
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the mid-sigmoid (MS) colon (see online supplementary
information (SOI); section 1). Endoscopists judged on
macroscopic appearance which polyps were adenoma-
tous, all judgements were independently confirmed by a
histopathologist and non-adenomatous samples were
removed from the analysis. In lesion-free participants
biopsies were taken from the MS. Three biopsies were
taken at each site—two for proteomic analysis and one
for immunohistochemistry. Participants additionally pro-
vided a stool sample (while bowel habit was normal) for
assessment of faecal SCFA levels.
Intervention study (FACT INT)
An initial screening tool for fibre intake was developed
(DL and EAW, unpublished) to identify participants
with low dietary fibre intake (<12 g/day). The screening
tool was in the form of a brief food frequency question-
naire that asked about the consumption and portion
size of high fibre breads, (cereals, pasta, rice, vegetables
and fruit). Nine participants were included in the inter-
vention trial. Biopsies were taken during scheduled
endoscopy from MS only and either flash frozen for
protein analysis or formalin fixed for IHC. Diet at base-
line was assessed using a 4-day food diary (FD) which
confirmed low baseline fibre intake. A food replace-
ment strategy was used to increase fibre intake. The
high fibre intervention was 8 weeks in duration and
included an initial 2-week period when intake was
increased incrementally. Increased fibre consumption
was encouraged via supply and weekly delivery of
fibre-rich foods (cereals, breads, fruit, vegetables) dir-
ectly to the participants’ homes. Participants were
invited to choose their own foods from a list of high-
fibre foods and were offered advice as to how to incorp-
orate more fibre into their diets. Participants were pro-
vided with a simple fibre reckoner to assess their own
daily fibre intake and were asked progressively to
increase fibre intake, to achieve an equivalent of over
20 g/day by the end week of the intervention. FD,
endoscopy, biopsy and stool sampling were repeated at
the end of the intervention.
Biopsy lysis, pooling and fractionation
Colorectal pinch biopsies (∼5 mg) were suspended in
kinase buffer (50 mM Tris-HCl pH7.5; 10 mM MgCl2;
0.1 mM EDTA; 2 mM DTT) followed by homogenisation.
The lysate was centrifuged to provide crude separation
between the insoluble and soluble fractions. Resulting
fractions were grouped by diagnosis and region and
were ranked by faecal butyrate level and then pooled:
eight lysates (two each from four patients) were used in
each pool. Acetyl proteins were separated from other
soluble proteins using antibody immobilised to a Pierce
Seize matrix. The insoluble fraction, principally inter-
mediate filaments, was prepared using our integrated
workflow for iTRAQ-compatible analysis26 which modi-
fied the high-salt extraction technique of Achstaetter27
and Herrmann.28 The insoluble and soluble fractions
were analysed using iTRAQ workflows while acetyl pro-
teins were analysed by 2D gel electrophoresis (vide
infra). The workflow is summarised in figure 1.
Proteomic methods
iTRAQ workflow Proteomes were analysed using an iTRAQ
workflow as previously described.29 Briefly proteins were
reduced, alkylated and subject to proteolytic digestion using
trypsin prior to labelling using the iTRAQ 8 plex kit
(ABSciex, Warrington, UK), according to manufacturer’s
instructions. Peptide fractionation was undertaken using
Strong Cation Exchange on a BioLC HPLC system
(Dionex, Surrey, UK). Fractions were collected, dried and
stored prior for mass spectrometric analysis. Mass spectrom-
etry (MS) was performed using ESI-qQ-TOF-MS/MS plat-
forms (Bruker, Bremen, GmBH) coupled with an online
nano-flow liquid chromatography system (U3000, Dionex,
Camberley, UK). Protein identifications were obtained
using the the Phenyx software platform (GeneBio, Geneva)
to perform database searching against the human UniProt
(SwissProt, Trembl downloaded 11 May 2010) database. A
concatenated target-decoy database search strategy was also
employed to estimate the rate of false discovery rate,30 calcu-
lated to be 1% and as such were well within the 5% recom-
mended for reporting proteomic data.31
Mathematical, bioinformatic and statistical analysis
Hierarchical clustering and principal component ana-
lysis were performed to group the data based on the
degree of similarity between samples. Agglomerative
clustering using the squared Euclidean distance between
log10 iTRAQ ratios and smallest inter-cluster dissimilarity
linkage procedure was performed (Mathematica 7.0.0
for Mac). Statistically significant changes in protein level
were identified using our t test algorithm.32 Pathway ana-
lysis was undertaken using the Instance Browser in
Reactome.33 Protein interaction networks were analysed
using STRING V. 9.0.34 Statistical analysis of immunoblot
densitometry data and immunohistochemical data was
carried out in Microsoft Excel and SPSS.
Immunoblotting
Proteins were separated by SDS-PAGE and transferred to
PVDF. Membranes were incubated with primary antibody
solutions in blocking buffer. Primary antibodies used
include: keratin 19 (mAb3238, Millipore, UK); ApoA1
(Ab48647, Abcam, UK), M2PK (Ab38327, Abcam, UK);
GAPDH (AM4300, Ambion); and α-tubulin (Ab7792,
Abcam). Cross-reactions were visualised using
HRP-conjugated secondary antibodies (Dako),
Immobilon Western HRP substrate (Millipore, UK). A
Chemigenius Bioimaging system was employed for band
visualisation and densitometric analysis.
Immunohistochemistry for keratin 8
Our previously established protocols for keratin 8 immu-
nohistochemistry and scoring were used.35 Antigen
retrieval was performed on 4-micron formalin-fixed,
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paraffin-embedded sections with EDTA (1 mM, pH8) in
microwave at high power for 8 min. Sections were incu-
bated with primary antibody (K8 mouse monoclonal,
ab9023) and biotinylated secondary antibody (anti
mouse IgG, RTU Vectastain Universal). Detection was
performed using DAB kit (sk-4100Vector lab, UK).
RESULTS
Recruitment and participant demographics
The inclusion, exclusion criteria, justification and study
design have previously been reported.36 Of 81 male par-
ticipants attending for diagnostic colonoscopy were
recruited, 19 were excluded from pooling by butyrate
owing to a diagnosis of cancer (n=11), failure to provide
a stool sample (n=3), or bowel preparation other than
Kleanprep (n=5). Biopsies from participants prepared
for endoscopy with Picolax (n=5) were pooled separately
as bowel preparation influences proliferation of colon
epithelial cells.37 Colonoscopy was completed to the
caecal pole in all participants. Adenomatous polyps
(confirmed histologically) were present in 28 partici-
pants and macroscopically normal colonic mucosa in
the remaining 34. The morphometric and AD positional
data are shown in the SOI, section 4.
Pooling for proteomics was undertaken following
stratification by faecal butyrate concentration. Stool
samples were extracted and butyrate determined as pre-
viously described.35 38 There was no significant difference
in the normal and AD subject groups’ highest (15.5 mM
vs 13.0 mM) and lowest (0.9 vs 0.8 mM) mean butyrate
levels (SOI, section 4). Individuals were stratified by
faecal butyrate, and samples grouped by diagnosis/biopsy
location (normal MS, AD MS, CL and lesion AD).
Workflow
The workflow for this study is set out in figure 1. The insol-
uble fraction was processed to yield intermediate filament
(IF)-enriched material.26 The soluble fractions were pooled
in fours (empirically determined to yield analysable acetyl-
proteins by IP, data not shown). Samples from the highest
and lowest butyrate pools from normal participants, and
AD participants at each of the three biopsy sites (a total of
eight pools) were immunoprecipitated to yield a pooled IP
eluate (acetyl proteins), and a pooled flow-through (other
soluble proteins).
Figure 1 Experimental
workflow. The figure summarises
the workflow used in this study.
Participants recruited had
biopsies taken and provided stool
(for faecal butyrate) and diet
information. The frozen biopsies
were lysed to yield soluble and
insoluble fractions. The former
was pooled according to butyrate
and subject to
immunoprecipitation for acetyl
proteins, to yield an
acetyl-enriched and a soluble
fraction. The former was analysed
by 2DGE whereas the latter was
analysed by iTRAQ. The
insoluble fraction was processed
to yield IF and then analysed by
iTRAQ. iTRAQ, isobaric tags for
relative and absolute
quantification; 2DGE, two
dimensional gel electrophoresis;
IF, intermediate filament.
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For proteomic analysis, the insoluble and soluble
pools were analysed by 8-plex iTRAQ workflow; the IP
pools were analysed by 2DGE. IP pools were indicative
of a profound effect of bowel preparation on protein
modification (SOI, section 15) and this analysis was not
pursued further. Orthogonal validation was provided at
two tiers: (1) immunoblot analysis of the pooled protein
extracts analysed by iTRAQ and (2) IHC on archived
FFPE biopsy material for individual participants from
the study.
The insoluble proteome shows lesion-associated changes
in the keratin profile
A small number of studies have converged on keratins as
hallmarks of colorectal mucosal health7 we undertook a
proteomic analysis of the insoluble fraction which is
enriched for intermediate filament proteins, including
keratins.26 Samples grouped by diagnosis/biopsy loca-
tion (normal MS, AD MS, CL and lesion AD) and were
stratified by low (∼1mM) and high (∼14 mM) butyrate
(see above and SOI for concentrations). The iTRAQ
workflow identified 55 proteins were represented by ≥2
peptides (complete list: SOI, section 5). Intermediate
filament proteins, including keratins were present.
Principal component analysis (PCA) (figure 2Ai) of the
proteins and associated iTRAQ ratios across the data set,
indicated that the samples clustered clearly according to
butyrate status, with a single axis (component 2) distin-
guishing low from high butyrate. The data were further
analysed using a Euclidian agglomerative clustering
approach, the data suggested that the high-butyrate
group were more alike than the low-butyrate group.
Figure 2 iTRAQ analysis of the insoluble proteome shows effects of lesional proximity and butyrate level. Samples were
separated and relatively quantified by 8-plex iTRAQ. Global analysis of the data was undertaken by principal component analysis
(PCA) (panel A) and hierarchical clustering analysis (HCA) (panel B). PCA showed clustering by butyrate level with low butyrate
samples in the blue oval and high butyrate in the orange oval. HCA showed the high-butyrate samples were more alike than the
other samples. A protein interaction network was generated from the whole dataset (orphan nodes not shown) indicating proteins
interlinked with clusters around extracellular matrix (solid line), keratins (dashed line) and metabolism (dotted line). Significant
differences between samples according to lesional proximity and controlling for butyrate were computed and are shown in panel
C. Proteins listed in red are significantly downregulated, while those in green are upregulated. iTRAQ, isobaric tags for relative
and absolute quantification.
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Interacting protein networks were identified with
STRINGS DB (figure 2B and SOI, section 6).
Intriguingly, when all lines of evidence are considered
the entire intermediate filament proteome forms a
single interaction network, with clustering around the
keratin-vimentin and collagen centres in additional to a
metabolism cluster. A pathways analysis using Reactome
(SOI, section 7), indicated that collagen formation and
extracellular matrix organisation were well represented
(p=2.8×10−8 and 1.8×10−8, respectively). The pathway
for NCAM signalling in neurite outgrowth was very
highly represented (p=1.2×10−10). The data are consist-
ent with the proposal that IF networks form scaffolding
on which associated proteins organise and are regulated
to control metabolic activities.39
We hypothesised that the alterations in insoluble kera-
tins observed associated with lesions or butyrate level
could either reflect a reduction in total keratin in the
tissue, or could represent a shift in protein space into
the soluble phase. We therefore undertook undirected
and directed analyses of the soluble fractions to establish
whether changes in keratin were reflected across the
fractions (vide infra).
Parallel analysis of the soluble fraction reveals
observed changes in keratin are at protein level, not a
change in protein solubility.
SDS PAGE analysis of the soluble fraction indicated
that the proteins remained intact without degradation
or smearing and that no part of the mass range was dis-
torted (SOI section 8). The soluble proteome was ana-
lysed by iTRAQ (SOI section 9). Analysis using Instance
Browser showed that no pathways were particularly
enriched (SOI, section 10). PCA (figure 3Ai) shows that
the macroscopically normal tissues are much more
similar than the lesional tissue. These samples may be
further separated along linear axes. The dotted axis sug-
gests that one component alone can distinguish the
effects of butyrate on tissue. The solid axis demonstrates
separability of macroscopically normal tissue according
to the presence or absence of a lesion. Hierarchical clus-
tering analysis (HCA) suggested again that lesional
tissue is most divergent, but that within macroscopically
normal tissue, the effect of butyrate is greater than the
effect of lesional proximity (figure 3Aii). Protein inter-
action networks were built as described above. A large
network accounted for many of the proteins, with
several smaller clusters (SOI section 11). Significant
changes were analysed either by controlling for the
butyrate status and assessing the impact of lesion on the
proteome (figure 3C) or by controlling for the lesional
status and assessing the impact of butyrate on the prote-
ome (figure 3D). For clarity on cytoskeletal and related
proteins are shown, versions with complete listings
appear in the SOI (SOI, section 11). Venns show pro-
teins significantly altered at each site by high or low
butyrate.
Seven proteins were subject to orthogonal validation
by western immunoblot: keratin 8, keratin 19, α-tubulin,
ApoA1, M2PK, GAPDH and cofilin (SOI section 12).
The data show different responses to butyrate with pro-
gressive lesional proximity. Assessment of the effect of
lesional proximity on ApoA1, tubulin and keratins 8
and 19 was undertaken (SOI, section 13). ApoA1 and
α–tubulin show a consistent trend of increased expres-
sion with transition from normal to field to AD tissue
(SOI, section 13). In contrast keratins 8 and 19 show a
consistent trend towards downregulation across the
same series.
Data for keratin were extracted each iTRAQ to allow
comparison of the changes observed between the
soluble and insoluble fractions in the same the same
subject pools were undertaken. Analysis revealed consist-
ent trends in data (figure 4A), supporting a model
whereby changes in keratin reflected the change in the
total level of protein in association with a lesion or levels
of butyrate. Further orthogonal validation by antibody-
based methods (western immunoblotting, immunohisto-
chemistry) was undertaken (figure 4B–F). Soluble frac-
tion pools were analysed by western immunoblot (figure
4Bi) for keratin 8 and keratin 19. Quantification
revealed that their level is constant between the MS and
CL sampling positions, but that in lesions levels are sig-
nificantly reduced (figure 4Bii). In the insoluble frac-
tion, analysis of the proteomic data (figure 4C)
indicated that alteration in keratin 8 and 18 was pro-
nounced around lesions and that this was also a function
of butyrate status. Immunoblot of keratin 8 and 18 in
insoluble samples (figure 4C) shows that the keratin 8
immunoreactivity profile was markedly different to the
soluble form: in the insoluble material the keratin 8
pool was represented by multiple bands in the 50 kDa
region. Samples extracted from lesional tissue had lost
some of the higher molecular weight forms, and lower
bands appeared, suggestive of proteolysis. The immunor-
eactivity profile of low butyrate samples from macroscop-
ically normal tissue resembled the lesional tissue, with
loss of the higher molecular weight forms of keratin.
The immunoblots suggest reduction is greater in low
butyrate conditions.
Since the trend is the same in the soluble and insol-
uble fractions (using iTRAQ and western immunoblot
analysis) the hypothesis of change in cellular level of
each of K8, K19 is a better fit to the data. To assess
whether changes were reflected at a histological level
and to allow analysis at individual subject level in
unpooled samples, FFPE sections were assessed using
our protocol.35 Figure 4Ei and ii show examples of
crypts with strong and deep staining and weak and
shallow staining, respectively, reflecting the scoring cri-
teria developed: crypt depth (KCD), crypt intensity
(KCI) and surface intensity (KSI) (ibid.). Analysis in
figure 4Eiii, iv and v shows each end point against
lesional proximity in samples from MS (normal) MS
(AD present) and CL to AD. All outcomes were tested
statistically and revealed significant differences between
each measure and lesional proximity (p=0.019, p=0.014,
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p=0.045, respectively, Jonkheere-Terpstra test). As the
normal group was a mixture of individuals from the AD
surveillance and index colonoscopies, retrospective data
on history of AD was obtained (where available) and a
subgroup analysis undertaken. There were no significant
differences between any of the keratin end points
between subgroups (figure 5Fi-iii and SOI, section 14).
Taken together these data reveal significant differences
in expression of multiple keratins and their products as
a function of butyrate status and lesional proximity. The
similarity between the sporadic and surveillance sub-
groups suggests that the changes observed associated
with presence of a lesion may be reversible by lesional
resection.
Figure 3 iTRAQ analysis of the
global soluble proteome shows
effects of butyrate and presence
of an adenoma. Samples were
separated and relatively
quantified by 8-plex iTRAQ.
Global analysis of the data was
undertaken by principal
component analysis (PCA) (panel
Ai) and hierarchical clustering
analysis (HCA) (panel Aii). PCA
showed macroscopically normal
samples could be separated by a
single factor to distinguish high
from low butyrate (dashed axis)
and a straight line (function of two
factors) could separate normal
from lesion-associated samples.
Panel B hierarchical clustering
was used to group the data
based on the degree of similarity
between the samples analysed
using the complete iTRAQ data
set. Quantitative data were used
to identify significant differences
between the soluble proteome
samples according to lesional
proximity and controlling for
butyrate. Panel C shows
comparisons of lesion proximity in
high and low butyrate samples
and panel D shows changes
associated with butyrate level,
controlling for lesional proximity.
Proteins listed in red are
significantly down-regulated,
while those in green are
up-regulated. iTRAQ, isobaric
tags for relative and absolute
quantification.
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Figure 4 Integrative analysis of changes in keratin. Data on relative expression of keratins 8, 18 and 19 are extracted from the
isobaric tags for relative and absolute quantification (iTRAQ) analyses and presented in panel A to allow comparison of trends
across samples. Panel Bi shows immunoblot for keratin 8 and keratin 19 of different soluble fraction pools with varying mean
butyrate at the mid-sigmoid (MS), contralateral (CL) and adenoma (AD) biopsy sites. Bands were quantified by densitometry and
are represented in Bii, MS is used as the reference sample, levels at the CL wall and lesion AD are shown in the white and grey
bars respectively. Panel C shows immunoblot analysis of keratin 8 and 18 immunoreactivity in the insoluble fractions at varying
butyrate level (high and low). Comparative analysis of trend in change in the iTRAQ data for soluble and insoluble fractions is
shown in Panel D. FFPE sections were stained and scored for keratin 8. Panels Ei and Eii show representative sections for high
and how scores. Three aspects of keratin organisation were scored: surface intensity, crypt intensity and crypt depth.
Box-and-whiskers plots show distributions of each data for each end point between three different sample sets—mid-sigmoid
(normal and adenoma) and contralateral to adenoma. All end points the data showed significant differences
( Jonkheere-Terpstra). When the normal group were separated into new cases (sporadic—spor) or surveillance cases free from
pathology but with a history of adenoma (surveillance) there were no significant differences between end points.
8 Evans CA, Rosser R, Waby JS , et al. BMJ Open Gastro 2015;2:e000022. doi:10.1136/bmjgast-2014-000022
Open Access
A fibre intervention elevates keratin expression
As dietary fibre intake is associated with a reduced risk
of cancer,13 we assessed the effect of increasing fibre
intake on keratin expression. A visual protocol is shown
in figure 5A, and details are in the methods and refer-
ence.24 Mean fibre intake was very significantly
increased (figure 5B), although surprisingly little
effect was seen on levels of faecal acetate or butyrate
(figure 5Ci and iii), and a trend towards reduced pro-
pionate was noted (p=0.086, figure 5Cii). Soluble
protein fractions from these biopsies were extracted
and immunoprobed for K8 and K19 (figure 5D).
Expression of both proteins was higher following fibre
intervention.
DISCUSSION
In this study we have collected biopsies from participants
with and without a neoplasia at positions with various
proximities to the lesion. These were subject to a three-
tier proteomic analysis, with orthogonal validation by
immunoblot and immunohistochemistry and finally an
independent intervention trial. Our experimental
design reveals a very consistent pattern of decreased
global level of keratins in lesional tissue and with butyr-
ate concentration. Polymerised keratins are a key compo-
nent of IF, and occupy the insoluble fraction of lysed
material, whereas depolymerised forms may appear in
the soluble fraction. The consistent pattern of change
between these fractions is indicative of reduced global
Figure 5 A high-fibre intervention elevates keratin level. Panel A graphical protocol: participants were recruited to an 8-week
fibre intervention. Biopsies, food diary and faecal samples were collected at baseline and at exit from the intervention. Non-starch
polysaccharide intake was significantly increased (panel B), however, there were no significant effects on faecal acetate or
butyrate (Ci, Ciii) whereas propionate (Cii) approached a significant reduction. Levels of keratins 8 and 19 were measured by
immunoblot, in samples preintervention and postintervention. Owing to effects of SCFAs and diet on ‘housekeeping’ markers (not
shown), Coomassie staining of duplicate gels was used to show controlled loading of gels.
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level of keratin with lesional proximity. The protein
acetylation environment of epithelia will be influenced
by microenvironmental levels of butyrate.40 41 We and
others have also shown that keratins are themselves
acetylated10 42 and that keratin acetylation is associated
with depolymerisation.11 12 Our data also indicate that
keratin forms may be altered as a consequence of the
lesion and butyrate status: in lesional tissue the insoluble
keratins appeared to be degraded, an observation paral-
leled in low-butyrate conditions in lesion-free partici-
pants. This suggests a contributing chemoprevention
action of butyrate. Critically, keratin changes may remain
modifiable risk factors: the fibre intervention increased
keratin level and retrospective subgroup analysis implied
restoration of keratin postpolypectomy.
Changes in metabolic proteins were also noted. The
colonocyte utilises butyrate as a fuel source,43 proximity
to a lesion impacts on the expression profile of meta-
bolic enzymes, possibly indicating local areas of Warburg
metabolism in a primarily β–oxidative tissue. Alterations
in pyruvate handling may change the functional thresh-
old for butyrate’s histone deacetylase (HDAC) inhibitory
activity.41
An integrative model for pre-neoplastic changes
Figure 6 shows an integrative model accounting for para-
meters we report in the context of the wider literature.
Keratins are responsive to butyrate resulting in changed
expression and polymerisation, however, we have also
recently reported upregulation of keratin 8 in response
to inflammation in active colitis (Corfe et al submitted to
Journal of Pathology). Subclinical inflammation is a risk
factor for carcinogenesis and has recently been shown
to impact on fatty acid oxidation.44 The extracellular
matrix, contributes to cell viability signalling, and alters
flexibility in the neoplastic colon, interactions with and
may signal via keratins. As such the metabolic, inflamma-
tory and extracellular matrix environments may all
impact on keratin at the levels of expression, polymerisa-
tion and degradation. The inflammatory and metabolic
environments are partly a function of diet and the
microbiome: diet may directly influence inflammation
(eg, through imbalance of ω-3 and ω-6 inter alia), and
carbohydrate and fibre and the microbiome together
mediate the levels of SCFA in the gut. We propose a
model wherein modifiable risk factors may exert sub-
clinical effects on the colonocyte, exhibited or inte-
grated through changes in keratin and intermediate
filament function. In turn such changes may form a
positive feedback loop, accelerating dysbiosis or
inflammation.
Our data provide direct molecular evidence of field-
changes. In the preneoplastic colon these events
remain, in principle, modifiable and offer a therapeutic
window. Future research should address whether such
changes are cause or effect of neoplasm.
Figure 6 Integrative model of
impact of microenvironment on
keratin and functional
consequences.
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